328 related articles for article (PubMed ID: 17357254)
1. Nonreceptor tyrosine kinases in prostate cancer.
Chang YM; Kung HJ; Evans CP
Neoplasia; 2007 Feb; 9(2):90-100. PubMed ID: 17357254
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Lee LF; Guan J; Qiu Y; Kung HJ
Mol Cell Biol; 2001 Dec; 21(24):8385-97. PubMed ID: 11713275
[TBL] [Abstract][Full Text] [Related]
5. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
6. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
7. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
[TBL] [Abstract][Full Text] [Related]
8. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
10. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
12. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
14. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.
Guo W; Liu R; Bhardwaj G; Ma AH; Changou C; Yang JC; Li Y; Feng C; Luo Y; Mazloom A; Sanchez E; Wang Y; Huang W; Patterson R; Evans CP; Lam KS; Kung HJ
PLoS One; 2013; 8(8):e70910. PubMed ID: 23967135
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
[TBL] [Abstract][Full Text] [Related]
17. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
18. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
Ojemuyiwa MA; Madan RA; Dahut WL
Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
[TBL] [Abstract][Full Text] [Related]
20. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
